<DOC>
	<DOCNO>NCT00826358</DOCNO>
	<brief_summary>The purpose study evaluate safety compare pharmacokinetic parameter fix dose combination ABT-143 relative co-administration two monotherapies .</brief_summary>
	<brief_title>Comparison Bioavailability Fenofibric Acid Rosuvastatin From 5/45 mg Strength ABT-143 Relative That From Coadministration ABT-335 ( Fenofibric Acid ) 45 mg Rosuvastatin Calcium 5 mg</brief_title>
	<detailed_description />
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . A condition general good health 2 . BMI 19 29 1 . Currently enrol another clinical study 2 . Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Adverse event</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>